Skip to content

Parangipattai Rasayanam in the management of kaalaanjagappadai(psoriasis)

EVALUATION OF SAFETY AND EFFICACY OF A SIDDHA HERBAL PREPARATION PARANGIPATTAI RASAYANAM FOR KALANJAGAPADAI (PSORIASIS) AND ITS CLINICAL MANAGEMENT - PRM(PARANGIPATTAI RASAYANAM)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/011904
Enrollment
40
Registered
2018-02-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- KALANJAGAPADAI (PSORIASIS)

Interventions

Intervention1: PARANGIPATTAI RASAYANAM: 8 gms of Parangipattai Rasayanam administered orally twice a day for a period of 40 days. Control Intervention1: NIL: NIL

Sponsors

NATIONAL INSTITUTE OF SIDDHA TAMBARAM SANATORIUM CHENNAI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Erythema Thickness Scaling Ithching :with or without itching Auspitz sign + Candle crease sign + • Age : 20-60 years • Sex : Both male and female • Willing to give specimen of blood for the investigation whenever required. • Willing to participate in trial and signing consent by fulfiling the condition of proforma.

Exclusion criteria

Exclusion criteria: Hypertension Diabetes mellitus Cardiac disease Use of narcotic drugs Pregnancy and lactation Psoriasis with evidence of any other skin disease Psoriatic arthropathy Evidences of secondary infection in the lesions

Design outcomes

Primary

MeasureTime frame
GOOD OUTCOME- CLEARANCE OF LESIONS AND REDUCTION OF PASI SCORE FROM 3,4 TO 0,1. MODERATE OUTCOME- CLEARANCE OF LESIONS AND REDUCTION OF PASI SCORE FROM 3,4 TO 1,2. POOR OUTCOME- NO CLEARANCE OF LESIONS OR NO REDUCTION OF PASI SCORE.Timepoint: 40 DAYS

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr V MAHALAKSHMI

CENTRAL COUNCIL FOR RESEARCH IN SIDDHA

dr.rsramaswamy@gmail.com9444941489

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026